Evaluation of the carcinogenic effect of desloratadine in somatic cells of Drosophila melanogaster
DOI:
https://doi.org/10.33448/rsd-v14i6.49044Keywords:
Carcinogenesis, Doxorubicin, Drosophila melanogaster.Abstract
Introduction: Desloratadine, an efficient histamine H1 receptor antagonist, is widely used in the treatment of allergic reactions, acting as an antihistamine and anti-inflammatory agent. In addition to its anti-inflammatory properties, some studies have shown positive effects of this drug in inhibiting carcinogenesis pathways, which, added to the scarce literature on its biological effects on cancer cells, makes it a target of studies. Objective: Assess the toxicity and carcinogenic potential of the antihistamine Desloratadine. Methodology: Analyzes were performed using the test for detection of epithelial tumor clones (ETT) in somatic cells of Drosophila melanogaster. Thus, third instar larvae of D. melanogaster, descendants of the cross between wts/TM3 and multiple wing hair (mwh/mwh) strains, were submitted to a treatment with four concentrations of Desloratadine (1.56, 3.125, 6.25, and 12.50 mg/mL), and a negative control (osmosis reverse water) and a positive control (doxorubicin) were also included. Results: Desloratadine alone did not promote a significant increase (p>0.05) in the frequency of mutant spots. Conclusion: Under the present experimental conditions, Desloratadinedid not show a carcinogenic effect.
Downloads
References
Alam, K., Farasyn, T., Ding, K., & Yue, W. (2018). Characterization of liver- and cancer-type-organic anion transporting polypeptide (OATP) 1B3 messenger RNA expression in normal and cancerous human tissues. Drug Metabolism Letters, 12(1), 24–32.
Bansode, S. (2019). Cancer biology—Causes & biomarkers of cancer. Current Research in Oncology.
Brochado, G. (2016). Turnover celular e tolerância cardíaca à doxorrubicina no modelo animal: Influência do treino físico (Tese de doutorado). Faculdade de Desporto da Universidade do Porto, Portugal.
Demir, E., Turna, F., Kaya, B., Creus, A., & Marcos, R. (2013). Mutagenic/recombinogenic effects of four lipid peroxidation products in Drosophila. Food and Chemical Toxicology, 53, 221–227.
Döbbeling, U., Waeckerle-Men, Y., Zabel, F., Graf, N., Kündig, T. M., & Johansen, P. (2013). The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines. Experimental Dermatology, 22(2), 119–124.
Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A., & Fares, Y. (2020). Molecular principles of metastasis: A hallmark of cancer revisited. Signal Transduction and Targeted Therapy, 5(1), 28.
Farzam, K., Sabir, S., & O’Rourke, M. C. (2021). Antihistamines. In StatPearls. StatPearls Publishing.
Fritz, I., Wagner, P., & Olsson, H. (2021). Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Translational Oncology, 14(4).
Fritz, I., Wagner, P., Bottai, M., Eriksson, H., Ingvar, C., Krakowski, I., Nielsen, K., & Olsson, H. (2020). Desloratadine and loratadine use associated with improved melanoma survival. Allergy, 75(8), 2096–2099.
Fritz, I., Wagner, P., Broberg, P., Einefors, R., & Olsson, H. (2020). Desloratadine and loratadine stand out among common H1-antihistamines for association with improved breast cancer survival. Acta Oncologica, 59(9), 1103–1109.
Hassanpour, S. H., & Dehghani, M. (2017). Review of cancer from perspective of molecular. Journal of Cancer Research and Practice, 4(4), 127–129.
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021). Systemic immunity in cancer. Nature Reviews Cancer, 21, 345–359.
Hon, K. L., Leung, A. K. C., Ng, W. G. G., & Loo, S. K. (2019). Chronic urticaria: An overview of treatment and recent patents. Recent Patents on Inflammation & Allergy Drug Discovery, 13(1), 27–37.
Lehmann, M. (2003). Toxicidade genética das antraciclinas: Associação entre estrutura química e ação inibitória sobre a topoisomerase II (Tese de doutorado). Universidade Federal do Rio Grande do Sul, Porto Alegre.
Lu, J., Zhao, X. J., Ruan, Y., Liu, X. J., Di, X., Xu, R., Wang, J. Y., Qian, M. Y., Jin, H. M., Li, W. J., & Shen, X. (2024). Desloratadine ameliorates paclitaxel-induced peripheral neuropathy and hypersensitivity reactions in mice. Acta pharmacologica Sinica, 45(10), 2061–2076.
Ma, J., Qi, J., Li, S., Zhang, C., Wang, H., Shao, L., Yuan, X., & Sha, Q. (2020). Desloratadine, a novel antigrowth reagent for bladder cancer. Technology in Cancer Research & Treatment, 19.
Maciel, A. D., Magalhães, M. D., & Orsolin, P. C. (2017). Efeito modulador do óleo de copaíba (Copaifera officinalis L.) sobre a carcinogenicidade da doxorrubicina, avaliado por meio do teste para detecção de clones de tumores em Drosophila melanogaster. Revista de Ciências Médicas e Biológicas, 16(2), 157–161.
Nitiss, J. L. (2009). Targeting DNA topoisomerase II in cancer chemotherapy. Nature Reviews Cancer, 9(5), 338–350.
Park, J. H., Pyun, W. Y., & Park, H. W. (2020). Cancer metabolism: Phenotype, signaling and therapeutic targets. Cells, 9(10).
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica [e-book]. Ed. UAB/NTE/UFSM.
Ritter, J. M. (2020). Rang & Dale farmacologia (9ª ed.). Rio de Janeiro: Grupo GEN.
Santos, J. C., Silva, S. C., & Orsolin, P. C. (2019). Efeito modulador da Ritalina® (metilfenidato) sobre a ação carcinogênica da doxorrubicina em Drosophila melanogaster. Revista da Faculdade de Ciências Médicas de Sorocaba, 20(4), 207–211.
Shitsuka, R., Shitsuka, R. I. C. M., Shitsuka, D. M., & Shitsuka, C. D. W. M. (2014). Matemática fundamental para a tecnologia (2ª ed.). São Paulo: Érica.
Sousa, L., Batista, J. E. C., Franco, J. L., & Posser, T. (2020). Drosophila melanogaster como organismo modelo para estudos sobre reativadores de colinesterase in vitro. Anais do Salão Internacional de Ensino, Pesquisa e Extensão, 6(2).
Troyanova‐Wood, M., Gobbell, C., Meng, Z., Gasheva, O., Gashev, A., & Yakovlev, V. V. (2021). Assessing the effect of prolonged use of desloratadine on adipose Brillouin shift and composition in rats. Journal of Biophotonics, 14(1).
Trybus, E., & Trybus, W. (2024). H1 Antihistamines—Promising Candidates for Repurposing in the Context of the Development of New Therapeutic Approaches to Cancer Treatment. Cancers, 16(24), 4253.
Vasconcelos, M. A. (2020). Vitamina D3: Potencial modulador sobre a mutagenicidade e a carcinogenicidade induzida por doxorrubicina em Drosophila melanogaster e sinergismo com fármacos em sistema in vitro (Tese de doutorado). Universidade Federal de Uberlândia, Uberlândia.
Vasconcelos, M. A., Orsolin, P. C., Silva-Oliveira, R. G., Nepomuceno, J. C., & Spanó, M. A. (2017). Assessment of the carcinogenic potential of high intense-sweeteners through the test for detection of epithelial tumor clones (warts) in Drosophila melanogaster. Food and Chemical Toxicology, 101, 1–7.
Vieira, S. (2021). Introdução à bioestatística (6ª ed.). Rio de Janeiro: Guanabara Koogan.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ana Luísa Soares de Castro Melo; Priscila Capelari Orsolin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
